drugset
drugset / Trial / NCT06397027

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

NCT06397027 ↗

Phase 1 Recruiting 22 enrolled M.D. Anderson Cancer Center Kura Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain types of genetic mutations (changes).

Timeline

Start
2024-12-27
Primary completion
2028-12-31
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziftomenib Small molecule — Intravenous
Background Azacitidine Other / unclassified — Oral
Background Venetoclax Small molecule — Oral

Indications

refractory hematologic cancer